Cargando…
The Role of NF-κB and Bax/Bcl-2/Caspase-3 Signaling Pathways in the Protective Effects of Sacubitril/Valsartan (Entresto) against HFD/STZ-Induced Diabetic Kidney Disease
LCZ696 (valsartan/sacubitril) has the potential to slow the progression of diabetic kidney disease (DKD) according to previous reports. However, the renoprotective mechanism underlying LCZ696 remains unknown. This study aimed to investigate the therapeutic potential and underlying mechanism of LCZ69...
Autores principales: | Mohany, Mohamed, Ahmed, Mohammed M., Al-Rejaie, Salim S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717728/ https://www.ncbi.nlm.nih.gov/pubmed/36359384 http://dx.doi.org/10.3390/biomedicines10112863 |
Ejemplares similares
-
Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan)
por: Eadie, Ashley L., et al.
Publicado: (2021) -
Rhabdomyolysis After Coadministration of Atorvastatin and Sacubitril/Valsartan (Entresto™) in a 63-Year-Old Woman
por: Faber, Eve S., et al.
Publicado: (2016) -
Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?
por: Nikolic, Marina, et al.
Publicado: (2022) -
Sacubitril‐valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTO‐SAS study
por: Jaffuel, Dany, et al.
Publicado: (2021) -
Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design
por: Jaffuel, Dany, et al.
Publicado: (2018)